Corbus Pharmaceuticals Holdings (CRBP) Cash & Current Investments (2013 - 2025)

Corbus Pharmaceuticals Holdings' Cash & Current Investments history runs 13 years deep, the most recent figure standing at $27.8 million for Q4 2025.

• On a quarterly basis, Cash & Current Investments rose 123.63% year-over-year to $27.8 million in Q4 2025; TTM through Dec 2025 was $27.8 million, a 123.63% increase from a year earlier, with the FY2025 full-year figure at $27.8 million, up 123.63% from the prior year.
• Cash & Current Investments advanced to $27.8 million in Q4 2025 per CRBP's latest filing, from $25.8 million in the prior quarter.
• Across five years, Cash & Current Investments topped out at $159.4 million in Q3 2024 and bottomed at $3.1 million in Q1 2023.
• The 5-year median for Cash & Current Investments is $46.8 million (2022), against an average of $60.5 million.
• Across the five-year window, Cash & Current Investments surged 7742.96% in 2021 and plunged 92.65% in 2023, its largest moves.
• Year by year, Cash & Current Investments stood at $25.2 million in 2021, then jumped by 134.92% to $59.2 million in 2022, then tumbled by 64.68% to $20.9 million in 2023, then sank by 40.51% to $12.4 million in 2024, then soared by 123.63% to $27.8 million in 2025.
• Per Business Quant, the three latest CRBP Cash & Current Investments figures stand at $27.8 million (Q4 2025), $25.8 million (Q3 2025), and $116.6 million (Q2 2025).